Hanall Biopharma (009420) - Total Assets
Based on the latest financial reports, Hanall Biopharma (009420) holds total assets worth ₩201.82 Billion KRW (≈ $136.77 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hanall Biopharma - Total Assets Trend (2011–2024)
This chart illustrates how Hanall Biopharma's total assets have evolved over time, based on quarterly financial data. Also see market value of Hanall Biopharma for the company's overall valuation and market capitalisation.
Hanall Biopharma - Asset Composition Analysis
Current Asset Composition (December 2024)
Hanall Biopharma's total assets of ₩201.82 Billion consist of 40.1% current assets and 59.9% non-current assets. Review 009420 total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 7.7% |
| Accounts Receivable | ₩15.33 Billion | 7.2% |
| Inventory | ₩37.70 Billion | 17.7% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩51.81 Billion | 24.3% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Hanall Biopharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Hanall Biopharma (009420) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hanall Biopharma's current assets represent 40.1% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 7.7% of total assets in 2024, down from 14.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 24.0% of total assets, an increase from 2.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 24.3% of total assets.
Hanall Biopharma Competitors by Total Assets
Key competitors of Hanall Biopharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥29.95 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
ASPEN PHAR.UN.ADR /1 O.N.
F:LDZU
|
Germany | €128.04 Billion |
Hanall Biopharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.01 | 2.86 | 5.61 |
| Quick Ratio | 0.92 | 1.73 | 4.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩37.81 Billion | ₩56.05 Billion | ₩106.30 Billion |
Hanall Biopharma - Advanced Valuation Insights
This section examines the relationship between Hanall Biopharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.58 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -11.2% |
| Total Assets | ₩212.88 Billion |
| Market Capitalization | $1.60 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Hanall Biopharma's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hanall Biopharma's assets decreased by 11.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hanall Biopharma (2011–2024)
The table below shows the annual total assets of Hanall Biopharma from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩212.88 Billion ≈ $144.27 Million |
-11.21% |
| 2023-12-31 | ₩239.75 Billion ≈ $162.47 Million |
+12.32% |
| 2022-12-31 | ₩213.45 Billion ≈ $144.65 Million |
+7.54% |
| 2021-12-31 | ₩198.48 Billion ≈ $134.51 Million |
-9.84% |
| 2020-12-31 | ₩220.13 Billion ≈ $149.18 Million |
+15.02% |
| 2019-12-31 | ₩191.38 Billion ≈ $129.70 Million |
+17.92% |
| 2018-12-31 | ₩162.30 Billion ≈ $109.99 Million |
-3.79% |
| 2017-12-31 | ₩168.70 Billion ≈ $114.32 Million |
+35.25% |
| 2016-12-31 | ₩124.73 Billion ≈ $84.53 Million |
+6.49% |
| 2015-12-31 | ₩117.13 Billion ≈ $79.37 Million |
+34.36% |
| 2014-12-31 | ₩87.17 Billion ≈ $59.07 Million |
-10.91% |
| 2013-12-31 | ₩97.85 Billion ≈ $66.31 Million |
-21.26% |
| 2012-12-31 | ₩124.27 Billion ≈ $84.22 Million |
+17.85% |
| 2011-12-31 | ₩105.46 Billion ≈ $71.47 Million |
-- |
About Hanall Biopharma
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, … Read more